Tilray Brands, Inc. (TLRY) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reflect a positive sentiment overall. The company shows strong international growth, particularly in Europe, and is expanding its distribution footprint. The strategic partnerships and product innovations in the beverage and wellness segments are promising. Despite some uncertainties in cost management and market projections, the reaffirmed EBITDA guidance and strategic plans for cannabis rescheduling in the U.S. and international expansion are positive indicators. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.
Key Financial Performance
Net Revenue $206.7 million, an 11% increase year-over-year. Growth was across multiple businesses.
Cannabis Net Revenue $64.8 million, a 19% increase year-over-year. Driven by 73% growth in international cannabis revenue and 8% growth in Canadian adult-use and medical cannabis.
International Cannabis Revenue $24.1 million in net sales, a 73% year-over-year growth and 20% sequential growth. Driven by exceptional sales volume growth, including 100% increase in medical cannabis flower volume and 90% increase in medical cannabis oil volume.
Germany Cannabis Market Revenue 43% year-over-year growth. Overcame $7 million in price pressure due to evolving regulatory framework and significant price compression.
Tilray Pharma Business Revenue $83 million, a 35% year-over-year growth. Driven by portfolio optimization, mix, positive market trends, and increased medical device sales.
Canadian Adult-Use Medical Cannabis Revenue $40 million, an 8% year-over-year growth. Reflects strength of portfolio and resilience of commercial execution.
Beverage Net Revenue $42.6 million, compared to $55.9 million in the prior year. Decline due to margin-focused actions and industry-wide softness. However, operational improvements and cost savings of $33 million were achieved.
Wellness Net Revenue $16.4 million, a 16% year-over-year growth. Driven by value-added innovation and momentum in high-vol energy grade.
Gross Profit $55 million, a 6% year-over-year increase. Gross margin was 27%, compared to 28% last year.
Cannabis Gross Margin 40%, compared to 41% year-over-year. Largely flat due to price compression in international markets.
Distribution Gross Margin 12%, compared to 9% year-over-year. Increase due to favorable changes in product mix and higher average selling prices.
Beverage Gross Margin 32%, compared to 36% in the prior year. Decline due to lower overhead absorption rates and higher input costs, including aluminum costs.
Wellness Gross Margin 33%, compared to 32% year-over-year. Increase due to strategic price increases offsetting unfavorable sales mix changes.
Net Loss $25.2 million, a $768.3 million improvement compared to a $793.5 million loss year-over-year. Improvement driven by a one-time noncash impairment in the prior year.
Adjusted Net Income $2.4 million, compared to an adjusted net loss of $2.9 million in the prior year. Improvement of $5.3 million year-over-year.
Adjusted EBITDA $10.7 million, a 19% increase compared to $9 million last year. Reflects execution against strategic plan, particularly in international cannabis business.
Cash Flow Used in Operations $21.9 million, compared to $5.8 million last year. Increase due to inventory buildup ahead of seasonally stronger fourth quarter and accounts receivable for growing international cannabis business.
Cash, Restricted Cash, and Marketable Securities $264.8 million, with a net cash position of $3.5 million. Improved $40.2 million from a net debt position year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BrewDog Acquisition: Tilray acquired BrewDog, positioning itself as a $1.2 billion global revenue company. This acquisition strengthens Tilray's long-term growth profile and expands its global craft beverage platform.
New Cannabis Strains: Tilray launched new cannabis strains, 'Good Supply, Where's My Bike' and 'Blueberry Donuts,' which became top 10 dried flower SKUs in British Columbia. Plans are in place to scale them nationally.
Portal Brand Launch: Introduced a new brand, Portal, featuring vapes and infused pre-rolls. National rollout is underway.
International Cannabis Growth: Tilray achieved $24.1 million in net sales for international cannabis, with 73% year-over-year growth and 20% sequential growth. Germany, the largest international market, grew 43% year-over-year.
Partnerships in Europe: Tilray partnered with Alliance Healthcare to expand reach to 16,000 pharmacies in Germany and with Smartway to expand pharmaceutical product availability in the U.K.
BrewDog Expansion: The BrewDog acquisition broadens Tilray's reach into untapped markets like the Middle East and Asia Pacific.
AI-Driven Cultivation: Tilray is modernizing its Canadian cannabis cultivation platform with AI-driven growing systems and next-generation genetics to improve yields and efficiency.
Project 420: Completed Project 420, delivering $33 million in annualized cost savings in the beverage segment, improving cost structure and margins.
Carlsberg Partnership: Tilray entered a strategic licensing partnership with Carlsberg to produce, market, and distribute Carlsberg brands in the U.S., starting January 2027.
Focus on High-Growth Categories: Tilray is prioritizing high-growth categories like vapes and beverages, with disciplined revenue generation and cost structure improvements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Environment: The company operates in highly regulated environments globally, facing cannabis regulatory reform in the U.S. and navigating constraints across international markets. This poses challenges to growth and operational flexibility.
Integration Challenges: The company acknowledges ongoing challenges with integrating acquisitions, which take time and effort to resolve, potentially impacting operational efficiency and strategic execution.
Price Compression: Significant price compression in international markets, particularly in Germany, has led to a $7 million impact on revenue, directly affecting profitability.
Macroeconomic Headwinds: Ongoing industry and macroeconomic headwinds are impacting financial performance, including input costs such as aluminum and other operational expenses.
Supply Chain Allocation: The company is reallocating supply from Canadian wholesale markets to higher-margin international markets, which could strain resources and operational focus.
Beverage Business Challenges: The beverage segment faces industry-wide softness, higher aluminum costs, and lower overhead utilization rates, which are affecting profitability and growth.
Federal Cannabis Legalization in Canada: After 7 years of legalization, the company is undergoing a comprehensive upgrade of its cultivation capabilities, which is still in transition and may impact margins and production consistency.
Hemp-Derived THC Regulatory Risks: Potential federal and regulatory changes in the U.S. after November 2026 could affect the company's hemp-derived THC beverage products, creating uncertainty in this segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Tilray Brands expects to achieve adjusted EBITDA guidance of $62 million to $72 million for fiscal 2026. The company anticipates continued revenue growth across multiple business segments, including cannabis, beverages, and wellness.
Cannabis Business Outlook: Tilray is well-positioned to expand its cannabis business globally as regulatory environments evolve, particularly in the U.S. The company plans to leverage its scale, infrastructure, and experience to capitalize on emerging opportunities. It expects continued growth in international cannabis markets, with a focus on medical cannabis and doctor-led distribution channels.
International Expansion: Tilray plans to expand its reach in international markets, including Germany and the U.K., through partnerships with Alliance Healthcare and Smartway. The company aims to increase its presence in pharmacies and distribution networks, enhancing its global medical cannabis platform.
Product Innovation and Launches: Tilray intends to scale new cannabis strains nationally and introduce additional genetics in fiscal 2027. The company also plans to roll out a new brand, Portal, featuring vapes and infused pre-rolls, to drive growth in key categories.
Beverage Business Growth: Tilray expects its partnership with Carlsberg, starting in January 2027, to drive immediate scale and revenue growth. The acquisition of BrewDog is anticipated to strengthen its global beverage platform and broaden its international reach, including entry into new markets such as the Middle East and Asia Pacific.
Operational Improvements: The company is focused on enhancing operational efficiencies through automation, centralized sourcing, and improved cultivation capabilities. These efforts aim to improve margins, strengthen product quality, and position Tilray ahead of industry trends.
Market Trends and Regulatory Changes: Tilray is monitoring U.S. cannabis rescheduling and regulatory developments. The company is prepared to participate in pilot programs and adapt to potential changes in federal and regulatory frameworks.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is Tilray managing the balance between supporting its international cannabis business and stabilization in Canada?
A:Tilray is increasing its grow capacity in Canada with facilities in Gatineau and Cayuga, while also improving yields and modernizing operations. In Europe, the Cantanhede facility in Portugal and the German facility are producing high-quality yields. Tilray is addressing price compression and ensuring consistent supply in Europe, aided by faster permit processes in Portugal. The company has ample supply to meet demand in both Canada and Europe.
Q:Is there a new project following the completion of Project 420?
A:Yes, Tilray continues to pursue cost-saving initiatives, including rationalizing plants and distributors, and leveraging scale from acquisitions like BrewDog. The company has grown its beer business significantly and plans to achieve additional cost savings through integration and optimization.
Q:What drove the 73% international growth and 43% growth in Germany?
A:The growth was driven by supply and demand, with some shipments delayed due to permits. Tilray has improved its supply consistency and offers high-quality flower and oils at competitive prices. The company is also expanding into new markets like Poland, the U.K., Spain, and France.
Q:How is Tilray managing rising aluminum costs and other supply chain challenges in its beverage segment?
A:Tilray is hedging 65%-75% of its aluminum purchases a year in advance. The company is leveraging scale from acquisitions like BrewDog and Carlsberg to negotiate better contracts for hops, cans, and other materials. It is also monitoring fuel costs and other potential headwinds.
Q:How are distribution gains from spring shelf resets tracking?
A:Tilray has gained and lost distribution space, particularly in the craft beer category. The company is focusing on new SKUs and innovation, with significant gains at retailers like Walmart, Kroger, and Albertsons. Tilray aims to be a bigger player in a smaller, more focused set of products.
Q:What are the key improvements at Tilray Pharma and how are they leveraging CC Pharma for cannabis in Germany?
A:Tilray Pharma is focusing on high-velocity, high-margin SKUs and expanding its medical cannabis portfolio. CC Pharma has increased its pharmacy reach from 13,000 to 16,000 drugstores and is vertically integrated, allowing Tilray to grow, brand, and distribute its products efficiently. Automation in purchasing and in-house packaging improvements are also contributing to growth and margin improvements.
Q:What is the revenue contribution from BrewDog assets and how does it bridge to the $1.2 billion run rate?
A:BrewDog assets contribute $225-$250 million in revenue. The remaining growth to the $1.2 billion run rate comes from organic growth and other acquisitions. Tilray acquired BrewDog's U.K., Ireland, and U.S. distribution and brewpubs, among other assets.
Q:What is Tilray's outlook on potential changes to hemp regulations and the CMS program in the U.S.?
A:Tilray anticipates either an extension of current regulations or new legislation regulating THC levels. The company is prepared to enter the CMS program with its existing CBD products, pending FDA approvals and regulatory clarity.
Q:What is the outlook for alcohol gross margins and how does it account for BrewDog and Carlsberg integration?
A:Current margins represent the bottom, with improvements expected as overhead utilization rates increase. The integration of BrewDog and Carlsberg is expected to enhance margins through scale and procurement efficiencies.
Q:What are the advantages of being vertically integrated in Germany's cannabis market?
A:Tilray's vertical integration allows it to ensure consistent supply, manage costs, and maintain quality. CC Pharma's network of 16,000 pharmacies and direct-to-pharmacy sales provide a competitive edge. Tilray also has a strong on-ground presence with teams working with prescribers and pharmacies.
Q:How is Tilray leveraging its brewpub footprint for growth?
A:Tilray views brewpubs as a marketing tool to build brand awareness and customer engagement. The company plans to upgrade existing brewpubs, explore franchising opportunities, and use them to promote its products, including non-alcoholic beverages.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear growth rate for Germany's cannabis market, citing uncertainties and ongoing opportunities in other European markets. Additionally, they did not specify the exact impact of aluminum cost hedging on margins or provide detailed financial projections for the integration of BrewDog and Carlsberg.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BrewDog craft
Carlsberg
Portal
Tilray Brands
awareness
beverage platform
brand portfolio
brewer
brewing
cannabis flower
cannabis oil
cannabis result
core
cultivation capability
discipline
foundation
generation
industry
leader
legislator regulator
measure
momentum fundamental
pilot program
press release
priority
profitability
reach
roll
scale infrastructure
vapes
volume cannabis
wellness
TLRY Transcript
Tilray Brands, Inc. (TLRY) Q3 2026 Earnings Call Transcript
Positive4-1
The earnings call summary and Q&A reflect a positive sentiment overall. The company shows strong international growth, particularly in Europe, and is expanding its distribution footprint. The strategic partnerships and product innovations in the beverage and wellness segments are promising. Despite some uncertainties in cost management and market projections, the reaffirmed EBITDA guidance and strategic plans for cannabis rescheduling in the U.S. and international expansion are positive indicators. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.
Aritzia Inc. (ATZ:CA) Q3 2026 Earnings Call Transcript
Positive1-8
Earnings results show strong financial performance with significant growth in gross profit, EBITDA, and cash position. The successful app launch and international expansion plans further support a positive outlook. Despite some uncertainties in guidance, the overall sentiment from the Q&A is optimistic, with plans for store openings and margin expansion. Given the company's market cap, the stock is likely to experience a positive movement between 2% to 8% over the next two weeks.
Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call highlights several positive elements: strong growth in Canadian and European markets, strategic international expansion, and a focus on higher-margin opportunities. The Q&A session further supports this with insights into market share gains, price stabilization, and a promising outlook for CC Pharma. Despite some challenges in the beer segment, the company's diversified strategy and international growth potential present a positive sentiment. Given the market cap, these factors suggest a likely positive stock price movement in the short term.
Tilray Brands, Inc. (TLRY) Q1 2026 Earnings Call Transcript
Positive10-9
The earnings call summary reveals positive financial performance with revenue growth across segments, improved cash flow, and strong liquidity. The Q&A section highlights management's proactive strategies in addressing international growth challenges, potential U.S. market opportunities, and leveraging digital assets. Despite some unclear responses, the overall sentiment is positive, supported by market expansion plans, particularly in Europe and the U.S. The market cap suggests moderate volatility, leading to a prediction of a 2% to 8% stock price increase over the next two weeks.
TLRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
